Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
VELCADE/m^2 · 1 trial · 1 indication
PFS was defined as the interval between the date of randomization and the date of progressive disease (PD) or death, whichever occurred first. PD was based on the assessment of an Independent Review Committee.
| Arm | Type | Description |
|---|---|---|
| R-CHOP | ACTIVE_COMPARATOR | Rituximab 375 mg/m\^2, Cyclophosphamide 750 mg/m\^2, Doxorubicin 50 mg/m\^2, Vincristine 1.4 mg/m\^2, and Prednisone 100 mg/m\^2 |
| VcR-CAP | EXPERIMENTAL | Rituximab 375 mg/m\^2, Cyclophosphamide 750 mg/m\^2, Doxorubicin 50 mg/m\^2, VELCADE 1.3 mg/m\^2, and Prednisone 100 mg/m\^2 |
| Name | Type | Description |
|---|---|---|
| Rituximab 375 mg/m^2 | DRUG | Intravenous rituximab 375 mg/m\^2 on Day 1 of a 21-day (3 week) cycle for 6 cycles. |
| Cyclophosphamide 750 mg/m^2 | DRUG | Intravenous cyclophosphamide 750 mg/m\^2 on Day 1 of a 21-day (3 week) cycle for 6 cycles |
| Doxorubicin 50 mg/m^2 | DRUG | Intravenous doxorubicin 50 mg/m\^2 on Day 1 of a 21-day (3 week) cycle for 6 cycles |
| VELCADE 1.3 mg/m^2 | DRUG | Intravenous VELCADE 1.3 mg/m\^2 on Days 1,4,8, and 11of a 21-day (3 week) cycle for 6 cycles |
| Prednisone 100 mg/m^2 | DRUG | Oral prednisone 100 mg/m\^2 on Day 1 to Day 5 of a 21-day (3 week) cycle for 6 cycles |
| Vincristine 1.4 mg/m^2 | DRUG | Intravenous vincristine 1.4 mg/m\^2 on Day 1of a 21-day (3 week) cycle for 6 cycles. Maximum of 2 mg. Participants could receive 8 cycles if a response was initially documented at the Cycle 6 assessment. |
Inclusion Criteria: * Male or female patients 18 years or older (the patient must be at least the legal age limit to be able to give informed consent within the jurisdiction the study is taking place) * Diagnosis of mantle cell lymphoma MCL (Stage II, III or IV) as evidenced by lymph node histology...
VELCADE is a small molecule being studied for use in Non-Small Cell Lung Cancer, Mantle Cell Lymphoma, and Amyloidosis. It is an investigational drug in clinical development for these conditions. VELCADE is developed by Takeda Pharmaceutical Company Limited.
VELCADE is a small molecule therapeutic. Its specific molecular target has not been disclosed in the available clinical trial information. The drug is being evaluated in clinical studies for Non-Small Cell Lung Cancer, Mantle Cell Lymphoma, and Amyloidosis.
VELCADE is developed by Takeda Pharmaceutical Company Limited, which trades under the ticker TAK. The company is conducting clinical trials of VELCADE for Non-Small Cell Lung Cancer, Mantle Cell Lymphoma, and Amyloidosis.
VELCADE is in Phase 1 clinical development. It has completed one Phase 1 trial, one Phase 2 trial, and one Phase 3 trial. VELCADE is not approved and remains investigational for the studied indications.
VELCADE has been studied in clinical trials including NCT00298766, an open-label Phase 1/2 study in patients with light-chain (AL)-amyloidosis, and NCT00722137, a Phase 3 study in patients with newly diagnosed Mantle Cell Lymphoma. These trials are completed.
VELCADE is also known as bortezomib. Clinical trials refer to the drug as VELCADE for injection and VELCADE (bortezomib). It is being studied for Non-Small Cell Lung Cancer, Mantle Cell Lymphoma, and Amyloidosis.